Metraipolis › archive › dc_34e613d4468f
Engineered metallic hybrid nanozyme for advanced inflammatory disease therapy — Europe PMC PMID:41362453
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41362453
- DOI
- 10.1016/j.mtbio.2025.102572
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T10:40:44.217Z
- SHA-256 of the archived text
37ebf927b143711ada5fb0e0a2ee28e552429cf508378cd339ededa4afb79450- Stable URL of this page
https://metraipolis.com/documento/dc_34e613d4468f
How to cite
Engineered metallic hybrid nanozyme for advanced inflammatory disease therapy — Europe PMC PMID:41362453 — Europe PMC (en), https://europepmc.org/article/MED/41362453 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_34e613d4468f (Metraipolis archive dc_34e613d4468f, sha256 37ebf927b143711ada5fb0e0a2ee28e552429cf508378cd339ededa4afb79450)
BibTeX
@misc{dc34e613d4468f,
title = {Engineered metallic hybrid nanozyme for advanced inflammatory disease therapy — Europe PMC PMID:41362453},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41362453},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_34e613d4468f; sha256 37ebf927b143711ada5fb0e0a2ee28e552429cf508378cd339ededa4afb79450},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41362453. Agents can read the archived copy with the MCP tool read_document.